Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A Randomized, Placebo Controlled, Double Blind Study of the Protective Effects of EPI-743 (VincerinoneTM) on Noise-Induced Hearing Loss

NCT02257983 is registered in ClinicalTrials.gov with Edison Pharmaceuticals Inc as lead sponsor.

NCT NCT02257983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02257983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A Randomized, Placebo Controlled, Double Blind Study of the Protective Effects of EPI-743 (VincerinoneTM) on Noise-Induced Hearing Loss
Lead sponsor
Edison Pharmaceuticals Inc
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2014
Completion date
February 29, 2016
Enrollment
77 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

noise-induced hearing loss